UnicoCell Biomed (TPE:6794) has applied to the U.S. Food and Drug Administration (FDA) to amend the Phase three clinical trial protocol for its adipose-derived stem cell therapy ELIXCYTE-OA, for the treatment of knee osteoarthritis.
The company said it originally submitted the Phase three trial to the FDA on Sept. 13, 2022, and is seeking the amendment to support subsequent verification and registration processes.
UnicoCell did not disclose the accumulated R&D spending, citing licensing negotiations, and said the timeline for completing the trial will depend on the project's progress.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments